| Title | Date | Affymetrix and BGI Enter Strategic Collaboration to Co-Develop and Commercialize Genomic Microarrays for the Agricultural Community|
Collaboration to expand research and molecular breeding tools for
enhancing plant, crop, and livestock production outcomes
SANTA CLARA, Calif.--(BUSINESS WIRE)--Jan. 13, 2012--
Affymetrix, Inc. (NASDAQ:AFFX), announced today that it has signed a
Memorandum of Understanding (MOU) with BGI, the world’s largest genomics
organization, to enter into a strategic co-development and co-marketing
collaboration. The non-exclusive partnership will aim t... |
| 01/13/12 | Affymetrix to Acquire eBioscience| - eBioscience is a leader in flow cytometry for oncology and immunology research reagents, with double-digit historical revenue growth and EBITDA margins of ~ 30% -
Dr. Frank Witney’s Customer Letter (pdf)
SANTA CLARA, Calif., Nov 30, 2011 (BUSINESS WIRE) -- Affymetrix, Inc., (NASDAQ:AFFX) today announced that it has signed a definitive agreement to acquire eBioscience, Inc., a privately-held San Diego, CA-based company with an industry-leading position in flow cytometry and immunoassay... |
| 11/30/11 | Affymetrix Completes Strategic Licensing Agreement with Genisphere for Proprietary MicroRNA Reagents|
Affymetrix miRNA Reagent Kit agreement expands its portfolio for
novel biomarker discovery and furthers its leadership strategies in the
miRNA gene expression markets
SANTA CLARA, Calif.--(BUSINESS WIRE)--Nov. 17, 2011--
Affymetrix®, Inc. (NASDAQ:AFFX) announced today at the Association of
Molecular Pathology (AMP) conference that they have entered into an
exclusive agreement with Genisphere®,
LLC, to offer the company’s proprietary ... |
| 11/17/11 | Affymetrix Enables Analysis of Challenging Sample Types Through Exclusive Agreement With Genisphere|
Agreement provides highly sensitive and reproducible RNA
amplification and labeling solutions for FFPE samples and is optimized
for gene expression analysis on Industry-leading array
SANTA CLARA, Calif.--(BUSINESS WIRE)--Nov. 16, 2011--
Affymetrix®, Inc. (NASDAQ:AFFX) announced today that it has entered into
an exclusive, worldwide licensing agreement with Genisphere®,
LLC, for RNA amplification and labeling technology to address
chall... |
| 11/16/11 | Affymetrix Reports Third Quarter Results| SANTA CLARA, Calif., Nov 02, 2011 (BUSINESS WIRE) --
Affymetrix, Inc., (NASDAQ: AFFX) today reported its operating results for the third quarter of 2011. Total revenue for the quarter was $64.0 million, as compared to total revenue of $74.0 million in the third quarter of 2010.
The Company reported a net loss of $9.8 million, or $0.14 per diluted share, in the third quarter of 2011. This loss included impairment charges totaling $0.7 million, or $0.01 per diluted share, on investments as well... |
| 11/02/11 | Affymetrix Announces Cancer-Profiling Collaboration| 13,500-sample study using SNP Array 6.0 to be performed by the Broad Institute as part of TCGA
SANTA CLARA, Calif., Oct 31, 2011 (BUSINESS WIRE) --
Affymetrix, Inc. (NASDAQ:AFFX) today announced that the company has entered into an agreement with the Broad Institute to chart the genomic changes involved in more than 20 types of cancer as part of the Broad's work in The Cancer Genome Atlas (TCGA). The agreement will involve the processing of 13,500 cancer samples on the Affymetrix(R) Genome-... |
| 10/31/11 | Affymetrix Releases Axiom Genome-Wide Pan-African Array| The highest genomic coverage of African and African American genomes for disease association studies
SANTA CLARA, Calif., Oct 12, 2011 (BUSINESS WIRE) -- Affymetrix(R), Inc. (NASDAQ:AFFX) today announced at the ICHG/ASHG annual conference in Montreal, the worldwide launch of the Axiom(R) Genome-Wide Pan-African Array, the first commercial product to maximize genomic coverage of both common and rare alleles in populations of African ancestry, including West African, East African, and African A... |
| 10/12/11 | Affymetrix to Host Conference Call on November 2, 2011 to Announce Third Quarter Operating Results| SANTA CLARA, Calif., Oct 06, 2011 (BUSINESS WIRE) -- Affymetrix, Inc. (NASDAQ:AFFX) today announced its third quarter 2011 operating results will be reported on Wednesday, November 2, 2011, after market close. The company will also hold a conference call on the same day at 5:00pm ET.
A live webcast can be accessed by visiting the investor relations section of the company's website at http://www.affymetrix.com. Alternatively, investors and other interested parties may listen to the live confere... |
| 10/06/11 | Affymetrix Launches 18 New Microarrays for Gene Expression Analysis of Model and Applied Research Organisms| The personalized microarray solution with the newest content and simple data analysis tools for faster publishing
SANTA CLARA, Calif., Oct 06, 2011 (BUSINESS WIRE) --
Affymetrix(R), Inc. (NASDAQ: AFFX) today announced commercialization of 18 new array designs for whole-transcriptome analysis of model and applied research organisms that will allow scientists to obtain a more complete gene expression view than traditional 3' biased arrays. The new Affymetrix(R) Gene 1.1 ST Array Strips are cr... |
| 10/06/11 | Affymetrix Announces Federal Court Affirms Dismissal of Illumina Patent Infringement Lawsuits| SANTA CLARA, Calif., Aug 19, 2011 (BUSINESS WIRE) -- Affymetrix, Inc. (NASDAQ:AFFX) (the "Company") today announced that the U. S. Court of Appeals for the Federal Circuit has affirmed the dismissal of the patent infringement lawsuits brought against the Company by Illumina regarding U.S. Patent Nos. 7,510,841 and 7,612,020.
"We are pleased that the Federal Circuit has affirmed the District Court's prior rulings that Affymetrix does not infringe the asserted patents and dismissing Illumina's l... |
| 08/19/11 | Affymetrix Commercializes Next-Generation Transcriptome Array for Large-Scale Clinical Studies| Leading pharmaceuticals and research institutions gain early-access to high density GeneChip Human Transcriptome and Splice Junction Array
SANTA CLARA, Calif., Aug 08, 2011 (BUSINESS WIRE) -- Affymetrix, Inc. (NASDAQ:AFFX) today announced commercialization of the next-generation human transcriptome array demonstrated by Stanford University researchers to be superior to mRNA sequencing (RNA-Seq) in gene expression profiling studies. In multiple experiments using a clinically relevant transcri... |
| 08/08/11 | Affymetrix To Release Axiom Array Plates Optimized for NIH-funded Genotyping Study of 100,000 People| Array plates designed to increase understanding of risk factors associated with complex disease and enable predictive therapies
SANTA CLARA, Calif., Aug 01, 2011 (BUSINESS WIRE) -- Affymetrix, Inc. (NASDAQ: AFFX) today announced plans to commercialize four Axiom(R) population-optimized arrays used to analyze 100,000 samples collected from volunteers in one of the nation's largest and most diverse genomics projects funded by the National Institutes of Health (NIH). Each Axiom genotyping array... |
| 08/01/11 | Affymetrix Reports Second Quarter Results| - Company reports a 10% decline in revenue and a 9% decrease in operating expenses over Q2 2010, cash flow from operations was $14 million for the second quarter -
SANTA CLARA, Calif., Jul 27, 2011 (BUSINESS WIRE) -- Affymetrix, Inc. (NASDAQ: AFFX) today reported its operating results for the second quarter of 2011. Total revenue for the quarter was $64.7 million, as compared to total revenue of $71.7 million in the second quarter of 2010.
The Company reported a loss of $3.7 million, or $0... |
| 07/27/11 | Affymetrix Begins Shipment of Industry's First FDA-cleared Gene Profiling Reagents| Offers clinical toolkit to accelerate development and commercialization cycles for molecular diagnostic test developers
SANTA CLARA, Calif., Jul 12, 2011 (BUSINESS WIRE) -- Affymetrix, Inc. (NASDAQ:AFFX) today began shipping its FDA-cleared Gene Profiling Reagents. Affymetrix also announced the availability of the new Gene Profiling Array cGMP U133 P2, a version of the widely cited Human Genome U133 Plus 2.0 Array, as another component to its GeneChip(R) Instrument System, which is used by A... |
| 07/12/11 | Affymetrix Announces Preliminary Revenue for Second Quarter 2011| SANTA CLARA, Calif., Jul 06, 2011 (BUSINESS WIRE) -- Affymetrix, Inc. (Nasdaq: AFFX) today reported that based on preliminary financial data, the Company expects total revenue for the second quarter of 2011 to be in the range of $64-65 million. The Company expects product revenue for the second quarter of 2011 to be approximately $58-59 million, including consumable sales of approximately $55 million and instrument sales of approximately $3.5 million. Service revenue is expected to be about $5 m... |
| 07/06/11 |
|
